Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a
combination of extended-release depot naltrexone plus extended-release bupropion as a
potential pharmacotherapy for methamphetamine (MA) use disorder.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Walter Ling
Collaborators:
National Institute on Drug Abuse (NIDA) The Emmes Company, LLC The EMMES Corporation